hl BS， et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma： updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009：20：520–5.
8、伊布替尼胶囊说明书
9、Byrd JC， Brown JR， O’Brien S， et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 May 31.
10、Susan O’Brien， et al. Five-Year Experience With Single-Agent Ibrutinib in Patients With Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Presented on 3 December 2016. Available at： https：//ash.confex.com/ash/2016/webprogram/Paper89757.html. Last accessed November 2016.
11、IMBRUVICA？ (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent. Available at： http：//www.janssen.com/imbruvica-ibrutinib-awarded-prix-galien-2015-best-pharmaceutical-agent. |
